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We describe two cases of early toxic shock syndrome,
caused by the superantigen produced from methicillin-resistant
Staphylococcus aureus and diagnosed on the basis of an
expansion of T-cell-receptor Vβ2-positive T cells. One case-
patient showed atypical symptoms. Our results indicate that
diagnostic systems incorporating laboratory techniques are
essential for rapid, definitive diagnosis of toxic shock syndrome.
T
oxic shock syndrome (TSS) is a severe illness caused by
methicillin-resistant Staphylococcus aureus (MRSA) infec-
tion, usually during menstruation but also in the postpartum
period. S. aureus produces several superantigenic exotoxins,
including TSS toxin-1 (TSST-1), which activate a vast number
of T cells in a T-cell-receptor Vβ-selective manner (1,2).
Cytokines produced by T cells and activated by TSST-1 are
thought to cause the abnormal changes of TSS (1,2).
Polymerase chain reaction (PCR) analysis of peripheral blood
T cells from adults with TSS has shown a protracted expansion
of TSST-1–reactive Vβ2-positive T cells persisting for 4–5
weeks (3). TSS in neonates, referred to as neonatal TSS-like
exanthematous disease, has been shown by flow cytometric
analysis to involve an expansion of T-cell–receptor Vβ2-posi-
tive T cells (4,5).
Because many cases do not satisfy the strict diagnostic cri-
teria for TSS proposed by the Centers for Disease Control and
Prevention (6), revised clinical diagnostic criteria for TSS,
including probable cases, have been proposed (Table) (7). In
Japan, several clinicians have described a TSS-like clinical
entity that could not be diagnosed as TSS even according to the
revised criteria. 
We report two cases of TSS with puerperal infection that
could be diagnosed at the early stage of the clinical course by
detecting a marked expansion of T-cell–receptor Vβ2-positive
T cells, as measured by flow cytometric analysis. The symp-
toms of one patient were too complex to permit diagnosis
according to the clinical criteria without evaluation of the
TSST-1-reactive T cells. We discuss the role of T-cell analysis
in peripheral blood mononuclear cells in the diagnosis of TSS.
Case Reports
Case 1
A 29-year-old Japanese woman underwent a cesarean sec-
tion at a private clinic after premature membrane rupture. On
postpartum day 3, shock with hypotension (67/37 mmHg)
developed. No rash occurred during this period. She was trans-
ferred to the Maternal and Perinatal Center, Tokyo Women’s
Medical University Hospital. 
On admission, the patient was awake and alert, but her face
was pale. Her body temperature was 37°C, blood pressure was
104/80 mmHg, heart rate was 140 bpm, and respiratory rate
was 28 times/min. A pelvic examination showed a brownish
discharge from the cervix. The uterus was approximately 10 x
10 cm in diameter, with no tenderness. Her systolic blood pres-
sure subsequently decreased to 80 mmHg, respiratory rate
increased to 44 times/min, and body temperature rose to 39°C.
Mild hypoxemia (pO2 = 65 mmHg while breathing room air)
became apparent, and the cardiothoracic rate shown on a chest
x-ray film had increased to 54%. To treat shock, dopamine and
fresh frozen plasma were administered with antithrombin III
and antibiotic therapy (initially, pentocillin 2 g/day + panipen-
em/betamipron 1 g/day + amikacin 100 mg/day, and subse-
quently, panipenem/betamipron 1 g/day + vancomycin 1
g/day). The results of laboratory tests led to a suspected diag-
nosis of septic shock with disseminated intravascular coagu-
lopathy (Table). Therefore, ulinastatin and gabexate mesilate,
which possess both antifibrinolytic and anticoagulative effects,
were administered (8,9). Because the patient’s general condi-
tion did not improve, she was admitted to the intensive care
unit. 
On day 3 after admission to the intensive care unit, an
abscess was observed around the surgical wound. Bacteriologic
tests showed that the vaginal discharge was positive for MRSA,
and a preliminary diagnosis of TSS was made. Peripheral blood
mononuclear cells were stained with antibodies to CD3, CD4,
CD8, and T-cell-receptor–Vβ2 elements and examined for the
percentage of Vβ2-positive T cells by a flow cytometer as
described (4,5). Five hours after staining, a marked expansion
of Vβ2-positive–T cells, unrelated to the CD4:CD8 ratio, was
confirmed (Figure), indicating the definitive diagnosis of TSS
in the early clinical course. Rash and desquamation, important
clinical symptoms of TSS, did not develop. On day 7 after
admission, the patient was discharged from the intensive care
unit and entered the general ward. On day 17, intrapelvic
abscess was incised and drained. Subsequently, her general
condition improved. The percentage of Vβ2-positive–T cells
decreased gradually over the course of 5 weeks (Figure). She
has no long-term sequelae. MRSA isolated from this patient
was later confirmed to be positive for TSST-1. 
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A previously healthy 33-year-old Japanese woman had a
fever (38.4°C) 1 week after an uncomplicated spontaneous
vaginal delivery without episiotomy at a private clinic. She was
transferred to Tokyo Women’s Medical University Hospital. On
admission, the patient was awake and alert. Her body tempera-
ture was 38.8°C, blood pressure was 80/52 mmHg, heart rate
was 127 bpm, and respiratory rate was 28 times/min. 
A diffuse erythematous rash was present on the chest. It
spread to the face and extremities and resolved after 8 days. A
pelvic examination disclosed a brownish discharge from the
cervix. The uterus was approximately 6 cm x 8 cm in diameter,
with no tenderness. The laboratory test results and clinical
symptoms suggested a diagnosis of TSS (Table). To treat the
hypotension, dopamine and fresh frozen plasma were adminis-
tered. The patient also received antithrombin III, ulinastatin,
and gabexate mesilate as well as antibiotics (initially, imipen-
em/cilastatin 2 g/day + amikacin 200 mg/day, and subsequent-
ly, vancomycin 2 g/day). 
One day after admission, bacteriologic tests showed that
the vaginal discharge and breast milk were positive for MRSA.
On day 5 after admission, peripheral blood mononuclear cells
were examined for expansion of Vβ2 T cells. A marked expan-
sion of Vβ2 T cells was confirmed (Figure), indicating the
definitive diagnosis of TSS. The Vβ2-positive T cells gradual-
ly diminished to normal levels. Desquamation of the extremi-
ties occurred on day 11 after admission. From day 3 after
admission, the patient’s general condition improved gradually,
and she was discharged on day 14. She had no long-term seque-
lae. Isolates of MRSA isolated were later found to be TSST-
1–positive.
Discussion
Puerperal infection is a major cause of maternal death.
Postpartum nonmenstrual TSS has received attention as a
potential cause of puerperal infection (10–12). Knowing the
incidence of MRSAinfections in medical institutions would be
helpful. For example, Fujino et al. reported that 246 MRSAiso-
lates were obtained from 74 inpatients in December 2000 in a
Tokyo hospital with 27 wards and 925 beds (13). During the
past 4 years, no TSS cases have occurred in our department of
obstetrics and gynecology. The two patients in this report were
transferred from a private clinic. Although the incidence of TSS
is rare in our department, we are concerned that the incidence
is not rare in small private clinics. Our two cases may provide
important clues to the actual incidence of TSS in women with
puerperal infection. 
In both of our patients, the diagnosis of TSS was con-
firmed during acute illness on the basis of expansion of TSS-1-
reactive Vβ2 T cells in peripheral blood mononuclear cells.
Diagnosis solely on the basis of clinical symptoms was not pos-
sible in case 1 because of the absence of skin rash and desqua-
mation, cardinal symptoms of TSS, and the presence of signs of
severe multiple organ failure. In case 2, diagnosis of TSS was
straightforward because of typical clinical symptoms. The
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Table. Laboratory data on admission of case-patients 
Data 






Laboratory findings (normal range)      
    Leukocytes (µL) (5,000–8,500)  2,800  17,500 
    Platelets (x104/µL) (13–40)  12.2  19.8 
    C-reactive protein (mg/dL) (0–0.4)  46.4  22 
    Total protein (g/dL) (6.5–8.2)  3.8  5.9 
    Albumin (g/dL (3.8–5.1)  1.6  3 
    Aspartate aminotransferase (IU/L) (0–35)  30  51 
    Alanine aminotransferase (IU/L) (0–35)  10  53 
    Lactic dehydrogenase (IU/L) (200–450)  712  698 
    Blood urea nitrogen (mg/dL) (5–12)  29.5  12.4 
    Creatinine (mg/dL) (<0.8)  2.58  0.72 
    Uric acid (mg/dL) (1.2–4.5)  9.2  2.5 
    Sodium (mEq/L) (136–145)  135  133 
    Potassium (mEq/L) (3.5–5)  4.6  3.3 
    Chloride (mEq/L) (98–108)   104  99 
    Creatine kinase (IU/L) (10–70)  244   
    Prothrombin time (sec) (12–14)  11.7  13.7 
    Activated partial thrombosplastin time 
    (sec) (24–36)  36.7  43.2 
    Fibrinogen (mg/dL) (400–650)  674  668 
    Antithrombin-III (%) (70–120)  60  82 
    Fibrinogen degeneration product (µg/mL) 
    (<10)  8.8  11.7 
    D-dimer (µg/mL) (<0.2)   5.22  3.93 
    Thrombin/antithrombin complex (ng/mL) 
    (<3.0)  40  20.4 
Criteria for definite TSS  
(all criteria must be present)  No  Yes 
    >38.9°C  Yes  Yes 
    Rash with desquamation    Yes 
    Hypotension <90 mmHg  Yes  Yes 
    Clinical or laboratory abnormalities 
    (>3 organs) 
    Gastrointestinal     
    Hepatic  Yes  Yes 
    Muscular     
    Mucous membrane    Yes 
    Renal  Yes  Yes 
    Cardiovascular     
    CNS     
Criteria for probable TSS  No  Yes 
    >3 criteria and desquamation or >5 criteria 
     without desquamation     
        >38.9°C  Yes  Yes 
        Rash    Yes 
        Hypotension  Yes  Yes 
        Myalgia     
        Vomiting and/or diarrhea     
        Mucous membrane inflammation    Yes 
        Clinical or laboratory abnormalities      
        >2 organs     
        Gastrointestinal     
        Hepatic  Yes  Yes 
        Muscular     
        Mucous membrane    Yes 
        Renal  Yes  Yes 
        Cardiovascular     
        Central nervous system     severe multiple organ failure in case 1 may have suppressed the
development of skin reactions. Our report strongly suggests
that some TSS cases that cannot be correctly diagnosed because
of a complicated clinical picture. Our results indicate that diag-
nostic systems incorporating laboratory techniques are essen-
tial for the rapid, definitive diagnosis of TSS. 
Our experience suggests the necessity for better estimates
of the incidence of postpartum staphylococcal infections, TSS
associated with MRSA, and TSS that does not satisfy general-
ly accepted diagnostic criteria. Several clinical trials in fields
other than obstetrical infections with MRSAare now underway
in Japan to address these issues. 
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Figure. Results of T-cell–receptor Vβ2 positive T cells in two women with toxic shock syndrome. The percentages of Vβ2+ CD4+ cells (left panel)
and Vβ2+ CD8+ T cells (right panel) in peripheral blood mononuclear cells were determined after admission. Patient 1 (open circles) and patient 2
(closed circles) refer to the same cases as in the text and Table ; ● represents mean±standard deviation in healthy adults (four men and three
women). 
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